All In Biotech

Drug Trial Radar · NCT02190747

An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Last checked: Nov 20, 2026Latest source record: Feb 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

40

Actual

Start

Jul 14, 2014

Primary completion

May 23, 2016

Study completion May 23, 2016

Sponsor

Lead sponsor
Clementia Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Jul 15, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Fibrodysplasia ossificans progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in abnormal bone formation in muscles, tendons, and ligaments. Flare-ups begin early in life and may occur spontaneously or after soft tissue trauma, vaccinations, or influenza infections. Recurrent flare-ups progressively restrict movement by locking joints leading to cumulative loss of function and disability. Mouse models of FOP have demonstrated the ability of retinoic acid receptor (RAR) gamma agonists to prevent heterotopic ossification (HO) following injury. The purpose of the study is to evaluate whether palovarotene, an RAR gamma agonist, will prevent HO during and following a flare-up in subjects with FOP.

Conditions

  • Fibrodysplasia Ossificans Progressiva

Interventions

  • PalovaroteneDrug

    Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules will be opened and the contents added onto specific food.

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Responders at Week 6Time frame: Baseline (Day 1) and Week 6 (Day 42)

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • University of California San Francisco, Division of Endocrinology and Metabolism

    San Francisco, California

  • University of Pennsylvania, Center for Research in FOP & Related Disorders

    Philadelphia, Pennsylvania

  • Hôpital Necker-Enfants Malades, Department of Genetics

    Paris, France

  • The Royal National Orthopaedic Hospital, Brockley Hill

    Stanmore, Middlesex, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.